Meet the Quadruple Aim in Diabetes Care with In-office HbA1c and uACR

Better outcomes. Lower costs. Better patient experience. Better clinician experience.

Comprehensive diabetes-management solutions at the point-of-care

Gain key insights into your patient’s current status and drive guideline recommended test adherence:

DCA Vantage® Analyzer

CLIA-waived HbA1c

• Rapid assessment for glycemic control

CLINITEK Status® Connect System

CLIA-waived analyzer for routine urinalysis

• Rapid kidney health assessment:

CLINITEK® Microalbumin 2 Strip Albumin-to-creatinine ratio (ACR)

Total U.S. Population with Diabetes

The Prevalence of Diabetes Among U.S. Adults is on the Rise1

Help your patients reverse the trend

Customize your patient consultations to enhance physician-patient partnership toward improved outcomes. siemens-healthineers.us/chronicdisease

Auvelity is a rapid-acting oral antidepressant with proven efficacy at Week 1

Indication

Auvelity is indicated for the treatment of major depressive disorder (MDD) in adults.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

• Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies.

• Closely monitor all antidepressant-treated patients for clinical worsening, and emergence of suicidal thoughts and behaviors.

• Auvelity is not approved for use in pediatric patients.

Please see additional Important Safety Information and the Brief Summary of Prescribing Information on the following pages, including Boxed Warning for suicidal thoughts and behaviors.

Auvelity uses a new approach to treat MDD that is different from other oral antidepressants approved in more than 60 years1-3†

Auvelity is the first and only oral NMDA receptor antagonist for MDD1-3

Symptom improvement at Week 1 and sustained at Week 6*

• Patients taking Auvelity had significant change from baseline in the MADRS total score at Week 6 vs placebo (primary endpoint: LS mean change of -12.1 vs -15.9; P=0.002).1,4

Rapid remission starting at Week 2*

• Significantly more patients achieved remission with Auvelity at Week 2 vs placebo (key secondary endpoint: 17% (24/142) vs 8% (12/159); P=0.013).4

Demonstrated safety profile in controlled and open-label studies*‡

• The most common adverse reactions in a 6-week study (≥5% and >2x placebo) were: dizziness, headache, diarrhea, somnolence, dry mouth, sexual dysfunction, and hyperhidrosis.1

• Long-term safety up to 1 year in an open-label study was consistent with controlled studies.1,5-7